Showing results (251-260 of 667) with videos related to

Sort By:
Pageof 67
Hemasphere|December 4, 2024
Models for the marrow: A comprehensive review of AI-based cell classification methods and malignancy detection in bone marrow aspirate smearsTabita Ghete, Farina Kock, Martina Pontones, et al.
Hemasphere|December 3, 2024
Interferon gamma-mediated prevention of tumor progression in a mouse model of multiple myelomaZoltán Kellermayer, Sabrin Tahri, Madelon M E de Jong, et al.
Hemasphere|November 20, 2024
Monoclonal gammopathy of undetermined significance with multiple paraproteins: A population-based screening studySæmundur Rögnvaldsson, Jón Þ Óskarsson, Sigrun Thorsteinsdóttir, et al.
Hemasphere|March 19, 2025
Inhibition of the NLRP3 inflammasome using MCC950 reduces vincristine-induced adverse effects in an acute lymphoblastic leukemia patient-derived xenograft modelHana Starobova, Hannah McCalmont, Svetlana Shatunova, et al.
Hemasphere|October 23, 2024
Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemiaMarion Larue, Myriam Labopin, Thomas Schroeder, et al.
Hemasphere|October 9, 2024
Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cellsRomane Durand, Céline Bellanger, Géraldine Descamps, et al.
Hemasphere|September 5, 2024
Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypesJurrian K de Kanter, Alexander S Steemers, Daniel Montiel Gonzalez, et al.
Hemasphere|August 8, 2024
PD-L1+ macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacyAlexandre V Hirayama, Jocelyn H Wright, Kimberly S Smythe, et al.
Hemasphere|August 7, 2024
A cellular reporter system to evaluate endogenous fetal hemoglobin induction and screen for therapeutic compoundsThijs C J Verheul, Nynke Gillemans, Kerstin Putzker, et al.
Hemasphere|August 7, 2024
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 studyAndrew D Zelenetz, Wojciech Jurczak, Vincent Ribrag, et al.
Pageof 67